Elevation Biopharma

Eleftha 440mg Injection consists of Trastuzumab as an active constituent which is indicated for its use in HER 2 breast cancer. In HER 2 positive patients, the breast cancer cells are mostly composed of HER2 proteins that cause rapid development of cancer tumor by serving as a signal to the cancerous. This medication is also used to treat metastatic gastric cancer with increased levels of HER2 proteins.

Her 2 positive breast cancer are most aggressive in nature. The targeted therapy for her 2 positive breast cancer works by selectively targeting the proteins that are responsible for the growth, development, and spread of cancer. Use effective birth control during the treatment and for at least 7 months after the final dose.

Brand   Thiotop   Composition   Thiotepa Manufacturer    Packaging  Size Vial Strength5 0mg

Introduction to Bortlieva 3.5mg Injection

Bortlieva 3.5mg Injection is a chemotherapeutic medication that belongs to the class of drugs called Proteasome inhibitors.  It contains the active compound BORTEZOMIB. It is used to treat multiple myeloma and mantle cell lymphoma.  This medication is concomitantly used with other chemotherapy medicines like pegylated liposomal doxorubicin, rituximab, cyclophosphamide, doxorubicin, dexamethasone, prednisolone or thalidomide for patients who have not started treatment and are unsuccessful or ineligible for blood stem cell transplant treatment.

It is not recommended to take Bortlieva 3.5mg Injection if you are allergic to active compounds or any other ingredients of this medicine. It is not advised to take this medicine if you have a compromised immune system. If you have an active infection, let your doctor know before beginning any treatment.  It is not recommended to use Bortlieva 3.5mg Injection in children and adolescents. It is not recommended to use this medication in patients with hepatitis. Inform your doctor if you have gastrointestinal disorders, hepatic disorders, thrombocytopenia (low platelet count), neutropenia (low white blood cell count), tumor lysis syndrome (metabolic abnormalities that can occur as a complication during the treatment of cancer), neuropathy (nerve malfunction), cardiac disorders, severe lung problems, pulmonary disorders and posterior reversible encephalopathy syndrome disorders before beginning the treatment with this medication. You are advised to monitor blood counts and hepatic enzymes throughout the treatment period.

The use of Bortlieva 3.5mg Injection during pregnancy and breastfeeding is not recommended and will be determined by the doctor only if absolutely necessary as it may cause harm to the developing fetus. It is recommended to use effective contraceptive methods during the therapy and 3 months after completion. Inform your doctor if you are pregnant or planning to get pregnant to know about effective contraceptive methods.  It is necessary to inform your physician about all the medicines, over the counter drugs, vitamin and herbal supplements you are taking before the start of therapy.